Skip to content
Search for:
About
ENTERIN
LEADERSHIP
BOARD OF DIRECTORS
ADVISORS
Science
GUT-BRAIN AXIS
PARKINSON’S DISEASE
Clinical Trials
KARMET-PHASE 2B
RASMET-PHASE 2A
Research
LEAD PROGRAMS
PIPELINE
SCIENTIFIC PUBLICATIONS
News
Contact
CONTACT
CAREERS
Loading...
Enterin is aiming to become the first company
in the world to develop a novel drug that
repairs the
dysfunctional
gut-brain axis
in patients with neurodegenerative disease.
LEARN MORE
In preclinical models of Parkinson's Disease,
ENT-01 displaces
a-synuclein aggregates
and restores normal signaling between the gut and the brain.
LEARN MORE
Our lead molecule, ENT-01,
has recently met it's
primary endpoint
in a Phase 2b study for patients with Parkinson's Disease.
LEARN MORE
Our clinical data indicates that
repair the gut-brain axis is able to
significantly improve
quality of life
by influencing multiple non-motor symptoms that affect patients with
Parkinson's Disease and other neurodegenerative conditions.
LEARN MORE
Home
admin
2024-12-11T18:56:14+00:00
Page load link
Go to Top